Logo

ACRV

Acrivon Therapeutics, Inc. Common Stock

ACRV

Acrivon Therapeutics, Inc. Common Stock • NASDAQ
$2.36 ▲ 0.00% (+0.00)
Market Cap $74.47 M
52w High $8.00
52w Low $1.05
Dividend Yield 0%
P/E -1.11
Volume 235.82K
Outstanding Shares 31.56M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $19.387M ▼ $-18.234M ▲ 0% $-0.47 ▲ $-17.934M ▲
Q2-2025 $0 $22.349M ▲ $-21.006M ▼ 0% $-0.55 ▼ $-20.706M ▼
Q1-2025 $0 $21.351M ▼ $-19.68M ▲ 0% $-0.51 ▲ $-19.369M ▲
Q4-2024 $0 $24.651M ▼ $-22.831M ▼ 0% $-0.6 ▼ $-22.528M ▲
Q3-2024 $0 $25.14M $-22.441M 0% $-0.59 $-24.889M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $129.254M ▼ $145.299M ▼ $16.696M ▲ $128.603M ▼
Q2-2025 $137.423M ▼ $158.583M ▼ $15.546M ▼ $143.037M ▼
Q1-2025 $149.635M ▼ $176.349M ▼ $15.959M ▼ $160.39M ▼
Q4-2024 $179.48M ▼ $196.588M ▼ $19.802M ▲ $176.786M ▼
Q3-2024 $187.453M $214.684M $17.792M $196.892M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-18.234M ▲ $-12.283M ▲ $5.911M ▼ $-117K ▼ $-6.49M ▼ $-13.182M ▲
Q2-2025 $-21.006M ▼ $-16.61M ▲ $19.451M ▲ $-97K ▲ $2.744M ▲ $-17.103M ▲
Q1-2025 $-19.68M ▲ $-19.535M ▼ $19.214M ▲ $-343K ▲ $-664K ▲ $-19.593M ▼
Q4-2024 $-22.831M ▼ $-17.36M ▼ $14.412M ▼ $-647K ▲ $-3.595M ▼ $-18.187M ▲
Q3-2024 $-22.441M $-17.323M $16.011M $-1.504M $-2.591M $-18.312M

Five-Year Company Overview

Income Statement

Income Statement Acrivon is still a pure research-stage company with no product sales yet. Its income statement is driven almost entirely by research and development and supporting overhead costs, which together lead to steady operating losses each year. Losses have grown as the company has advanced its pipeline and platform, which is normal for an early-stage biotech but means that profitability is entirely dependent on future clinical success, regulatory approvals, or meaningful partnership income. The swings in per‑share losses likely reflect financing and share-count changes around the IPO rather than a fundamental shift in the business model, which remains pre-commercial and investment-heavy.

Balance Sheet

Balance Sheet The balance sheet is relatively simple and lean. Assets are modest and largely made up of cash and equivalents, with very little in the way of physical assets or long-term obligations. Debt is negligible, which reduces financial risk from interest and repayments. Shareholders’ equity has moved from negative to clearly positive, showing that past losses have been more than offset by new capital raised. However, the overall cash and asset base looks small compared with the long timeframes and high costs typical of oncology drug development, so the company’s financial cushion appears limited and may need to be reinforced over time through additional funding.

Cash Flow

Cash Flow Cash flows reflect a classic clinical-stage biotech profile: cash going out to fund research, trials, and operations, and no cash coming in from product sales. Operating cash outflows have been consistently negative but not extreme for a company at this stage, and there is essentially no spending on capital equipment, so free cash flow mirrors operating cash burn. This burn rate must be viewed against the available cash balance and expected ramp-up of trials; without new income sources, the company is likely to remain dependent on capital markets or partnerships to support its pipeline. Managing the pace of spending versus cash on hand is a key ongoing risk factor.

Competitive Edge

Competitive Edge Acrivon is trying to carve out a differentiated position in precision oncology by focusing on proteomics rather than just genetics. Its AP3 platform and linked OncoSignature companion diagnostics aim to pick out the patients most likely to respond to specific cancer drugs, including its own pipeline assets. If this works as intended, it could improve trial success rates and make its therapies more compelling for targeted groups of patients, which would be a real competitive edge. At the same time, the company operates in a crowded and well-funded field, competing with large pharma and other precision-medicine players. Its advantage depends heavily on demonstrating in clinical data that AP3 and OncoSignature meaningfully improve patient selection and outcomes, which is still being proven.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Acrivon’s story. The AP3 proteomics platform is designed to read the actual protein activity in tumors and then match that to specific drugs, and the company builds drug-specific OncoSignature tests on top of this. Lead programs like ACR-368 (a CHK1/2 inhibitor) and ACR-2316 (a dual WEE1/PKMYT1 inhibitor) are being advanced hand-in-hand with these diagnostics, which is a more tightly integrated approach than many peers take. The strategy could support multiple future drugs, new biomarkers, and co-development deals with larger companies. However, this is scientifically complex, clinically risky work: success requires not only that the drugs perform well, but also that the companion diagnostics are validated, gain regulatory acceptance, and are adopted in practice.

Summary

Overall, Acrivon is a very early-stage, high-uncertainty biotech built around a distinctive scientific idea rather than a commercial track record. Financially, it has no revenue, recurring losses, modest but clean balance sheet metrics, and a reliance on external funding to continue operations. Strategically, its focus on proteomics-driven precision oncology and tightly linked diagnostics is a meaningful differentiator, with several promising programs moving through clinical stages. The main positives are the innovative platform, clear scientific rationale, and limited balance sheet leverage; the main risks are clinical failure, regulatory hurdles, the cost and time needed to reach market, and the ongoing need to secure additional capital or partnerships as development progresses.

NEWS

November 13, 2025 · 4:10 PM UTC

Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Read more

October 22, 2025 · 4:15 PM UTC

Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference

Read more

October 1, 2025 · 4:30 PM UTC

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more